AstraZeneca’s Farxiga fails to get U.S. approval for Type-1 diabetes
British drugmaker AstraZeneca Plc said on Monday the U.S. Food and Drug Administration declined to approve its diabetes treatment, Farxiga, for use as a supplement to insulin in adults with a rare-type of the condition. Reuters Health News
In Charge of Animal Disease Study, and Surveillance Bureau, expert on Disease Study, Surveillance, Early Warning/Response, Client Training, and Development. Executive Officer for projects avoiding spread of diseases. Works at Iran Veterinary Organization; Veterinarian, 2000 - present.